Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Ansofaxine suppressed NSCLC progression by increasing sensitization to combination immunotherapy.
Int Immunopharmacol
January 2025
School of Medicine, Guizhou University, Guiyang 550025, China; NHC Key Laboratory of Pulmonary Immunological Diseases, Guizhou Provincial People's Hospital, Guiyang 550002, China. Electronic address:
Introduction: Depression negatively impacts the prognosis of various cancers, including lung cancer, by influencing antitumor immune responses and impairing immune cell function. Antidepressants may modulate the tumor immune microenvironment, enhancing immunotherapy efficacy. However, the specific mechanisms remain unclear.
View Article and Find Full Text PDFSplenic T2 signal intensity loss on MRI is associated with disease burden in multiple myeloma.
Eur Radiol
November 2024
Department of Medicine V, Multiple Myeloma Section, University Hospital Heidelberg, Heidelberg, Germany.
Article Synopsis
- - The study investigates how changes in spleen signal on various MRI sequences relate to the amount of plasma cell infiltration in the bone marrow of multiple myeloma patients, aiming to find a possible indicator for disease severity.
- - Researchers analyzed 45 newly diagnosed MM patients using whole-body MRI and found that spleen signal intensity negatively correlated with bone marrow plasma cell infiltration, meaning higher infiltration resulted in lower spleen signal.
- - Results suggest a significant association between spleen signal intensity, particularly on T2-weighted images, and tumor burden, providing potential insights for assessing disease in multiple myeloma patients.
Liver Function Test Results Correlate With Spleen Size in Patients With Infectious Mononucleosis.
Cureus
September 2024
Department of Orthopaedic Surgery, Stanford University School of Medicine, Stanford, USA.
Introduction: We aimed to evaluate the efficacy of measuring transaminase levels to determine the resolution of splenomegaly in athletes diagnosed with infectious mononucleosis (IM).
Methods: We collected serial aspartate aminotransferase (AST) and alanine transaminase (ALT) levels and ultrasound-measured spleen sizes in university athletes who had been diagnosed with IM. Our study included seven university-aged athletes from a single institution.
Impact of Empagliflozin on the Outcomes of β-Thalassemia Major in Patients With Type 2 Diabetes Mellitus: The THALEMPA Observational Study.
Cureus
September 2024
Department of Internal Medicine, Section of Hematology, Al-Nahrain University College of Medicine, Baghdad, IRQ.
Article Synopsis
- Beta-thalassemia major (β-TM) is a genetic disorder that leads to severe anemia and requires lifelong blood transfusions, often causing serious health issues. The THALEMPA study explored how empagliflozin (EMPA) affects patients with β-TM who also have type 2 diabetes mellitus (T2DM), focusing on disease severity and complications.
- The study involved 20 patients who were divided into an EMPA group, which received 10 mg of the drug, and a control group with standard care, monitoring various health parameters over three months.
- Results showed that EMPA significantly improved hemoglobin levels and reduced liver enzyme levels, serum ferritin, and uric acid levels, indicating potential
Real-World Use of Ruxolitinib in Patients with Myelofibrosis and Anemia or Thrombocytopenia at Diagnosis.
Acta Haematol
October 2024
Incyte Corporation, Wilmington, Delaware, USA.
Introduction: Ruxolitinib is approved for treatment of myelofibrosis. We evaluated ruxolitinib in patients with anemia (hemoglobin <10 g/dL) or thrombocytopenia (platelet count ≤100 × 109/L) at diagnosis.
Methods: This was a retrospective, secondary analysis of a Cardinal Health Oncology Provider Extended Network medical chart review of adults with myelofibrosis diagnosed between 2012 and 2016 who received first-line ruxolitinib.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!